CoChat
Sign Up
Cited by 33Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchRedox biology and oxidative stress

Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy

Open access
Chen, Yuan-Yuan, Wang, Min-Chang, Wang, Yan-Ni, Hu, He-He, Liu, Qing-Quan, Liu, Hai-Jing, Zhao, Ying-Yong·2020·Biomarker Research
DOI 10.1186/s40364-020-00218-zPMC PMC7488504
Open this paper in CoChat — free accountOpen PDF

Abstract

Aging and average life expectancy have been increasing at a rapid rate, while there is an exponential risk to suffer from brain-related frailties and neurodegenerative diseases as the population ages. Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide with a projected expectation to blossom into the major challenge in elders and the cases are forecasted to increase about 3-fold in the next 40 years. Considering the etiological factors of AD are too complex to be completely understood, there is almost no effective cure to date, suggesting deeper pathomechanism insights are urgently needed. Metabolites are able to reflect the dynamic processes that are in progress or have happened, and metabolomic may therefore provide a more cost-effective and productive route to disease intervention, especially in the arena for pathomechanism exploration and new biomarker identification. In this review, we primarily focused on how redox signaling was involved in AD-related pathologies and the association between redox signaling and altered metabolic pathways. Moreover, we also expatiated the main redox signaling-associated mechanisms and their cross-talk that may be amenable to mechanism-based therapies. Five natural products with promising efficacy on AD inhibition and the benefit of AD intervention on its complications were highlighted as well. Graphical Abstract:

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40364-020-00218-z

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For males, no significant GO terms were identified at 25% FDR; the strongest enrichment with nominal P<0.001 involved immune responses to accumulation of amyloid-β in the brain, such as regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell, and other biological processes recently implicated in AD such as response to angiotensin [

    “For males, we did not identify any significant GO terms at 25% FDR; the strongest enrichment with nominal P-value less than 0.001 involved immune responses to the accumulation of amyloid-β (Aβ) in the brain, such as regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell, and other biological processes recently implicated in AD such”

    From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [60]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 127

  1. [3]Cuperlovic-Culf M Badhwar A Recent advances from metabolomics and lipidomics application in Alzheimer's disease inspiring drug discovery Expert Opin Drug Discov 2020 15 3 319 331 31619081
  2. [4]Li T Braunstein KE Zhang J The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model Nat Commun 2016 7 12082 27373369 PMC4932197
  3. [5]Qiang W Yau WM Lu JX Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes Nature 2017 541 7636 217 221 28052060 PMC5233555
  4. [6]D'Souza Y Elharram A Soon-Shiong R Characterization of Aldh2 (−/−) mice as an age-related model of cognitive impairment and Alzheimer's disease Mol Brain 2015 8 27 25910195 PMC4409701
  5. [7]Wang X Sun G Feng T Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression Cell Res 2019 29 10 787 803 31488882 PMC6796854
  6. [8]Carvalho C, Cardoso S. Diabetes-Alzheimer s disease link: targeting mitochondrial dysfunction and redox imbalance. Antioxid Redox Signal. 2020. 10.1089/ars.2020.8056. 32098477 · DOI
  7. [9]Yan LJ Positive oxidative stress in aging and aging-related disease tolerance Redox Biol 2014 2 165 169 25460727 PMC4297947
  8. [10]Thapa A, Carroll NJ. Dietary modulation of oxidative stress in Alzheimer's disease. Int J Mol Sci. 2017;18(7):1583. PMC5536070 28753984
  9. [11]Lim WL Martins IJ Martins RN The involvement of lipids in Alzheimer's disease J Genet Genomics 2014 41 5 261 274 24894353
  10. [12]Nagata Y Hirayama A Ikeda S Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort Biomark Res 2018 6 5 29387418 PMC5778653
  11. [13]Morris G Walder K Puri BK The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders Mol Neurobiol 2016 53 7 4638 4658 26310971
  12. [14]Zou Y Watters A Cheng N Polyunsaturated fatty acids from astrocytes activate PPARγ signaling in cancer cells to promote brain metastasis Cancer Discov 2019 9 12 1720 1735 31578185 PMC6891206
  13. [15]Pryor WA Stanley JP Letter: a suggested mechanism for the production of malonaldehyde during the autoxidation of polyunsaturated fatty acids. Nonenzymatic production of prostaglandin endoperoxides during autoxidation J Org Chem 1975 40 24 3615 3617 1185332
  14. [16]Marnett LJ Lipid peroxidation-DNA damage by malondialdehyde Mutat Res 1999 424 1–2 83 95 10064852
  15. [17]Zhang S, He Y, Sen B, et al. Reactive oxygen species and their applications toward enhanced lipid accumulation in oleaginous microorganisms. Bioresour Technol. 2020:123234. 10.1016/j.biortech.2020.123234. 32245673 · DOI
  16. [19]Bazinet RP Laye S Polyunsaturated fatty acids and their metabolites in brain function and disease Nat Rev Neurosci 2014 15 12 771 785 25387473
  17. [20]Lee HJ Korshavn KJ Kochi A Cholesterol and metal ions in Alzheimer's disease Chem Soc Rev 2014 43 19 6672 6682 24710074
  18. [21]Williams T Borchelt DR Chakrabarty P Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease Mol Neurodegener 2020 15 1 8 32005122 PMC6995170
  19. [22]Corder EH Saunders AM Strittmatter WJ Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 1993 261 5123 921 923 8346443
  20. [24]Simons M Keller P De Strooper B Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons Proc Natl Acad Sci U S A 1998 95 11 6460 6464 9600988 PMC27798
  21. [25]Sheedy FJ Grebe A Rayner KJ CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat Immunol 2013 14 8 812 820 23812099 PMC3720827
  22. [26]Mapstone M Cheema AK Fiandaca MS Plasma phospholipids identify antecedent memory impairment in older adults Nat Med 2014 20 4 415 418 24608097 PMC5360460
  23. [27]Robinson AJ Hopkins GL Rastogi N Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3 Cancer Res 2020 80 5 937 949 31862780 PMC7611211
  24. [28]Liguori C Stefani A Sancesario G CSF lactate levels, tau proteins, cognitive decline: a dynamic relationship in Alzheimer's disease J Neurol Neurosurg Psychiatry 2015 86 6 655 659 25121572
  25. [29]Liguori C Chiaravalloti A Sancesario G Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease Eur J Nucl Med Mol Imaging 2016 43 11 2040 2049 27221635
  26. [30]Yakoub KM, Lazzarino G, Amorini AM, et al. Fructose-1,6-bisphosphate protects hippocampal rat slices from NMDA excitotoxicity. Int J Mol Sci. 2019;20(9):2239. PMC6540300 31067671
  27. [31]Catarina AV Luft C Greggio S Fructose-1,6-bisphosphate preserves glucose metabolism integrity and reduces reactive oxygen species in the brain during experimental sepsis Brain Res 2018 1698 54 61 29932894
  28. [32]Salminen A Haapasalo A Kauppinen A Impaired mitochondrial energy metabolism in Alzheimer's disease: impact on pathogenesis via disturbed epigenetic regulation of chromatin landscape Prog Neurobiol 2015 131 1 20 26001589
  29. [33]Parnetti L Reboldi GP Gallai V Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia Neurology 2000 54 3 735 737 10680813
  30. [34]Kim E Jung YS Kim H Metabolomic signatures in peripheral blood associated with Alzheimer's disease amyloid-β-induced neuroinflammation J Alzheimers Dis 2014 42 2 421 433 24898638
  31. [35]Isopi E Granzotto A Corona C Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology Neurobiol Dis 2015 81 214 224 25434488
  32. [36]Lanznaster D Mack JM Coelho V Guanosine prevents anhedonic-like behavior and impairment in hippocampal glutamate transport following amyloid-β1-40 administration in mice Mol Neurobiol 2017 54 7 5482 5496 27599498
  33. [37]Tasca CI Lanznaster D Oliveira KA Neuromodulatory effects of guanine-based purines in health and disease Front Cell Neurosci 2018 12 376 30459558 PMC6232889
  34. [38]Alonso-Andres P Albasanz JL Ferrer I Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology Brain Pathol 2018 28 6 933 946 29363833 PMC8028663
  35. [39]Wamser MN Leite EF Ferreira VV Effect of hypoxanthine, antioxidants and allopurinol on cholinesterase activities in rats J Neural Transm (Vienna) 2013 120 9 1359 1367 23400363
  36. [40]Bavaresco CS Chiarani F Wannmacher CMD Intrastriatal hypoxanthine reduces Na+,K+-ATPase activity and induces oxidative stress in the rats Metab Brain Dis 2007 22 1 1 11 17226099
  37. [41]Li N Liu Y Li W A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease J Ginseng Res 2016 40 1 9 17 26843817 PMC4703800
  38. [42]Du N Xu D Hou X Inverse association between serum uric acid levels and Alzheimer's disease risk Mol Neurobiol 2016 53 4 2594 2599 26084440
  39. [43]Lu N Dubreuil M Zhang Y Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study Ann Rheum Dis 2016 75 3 547 551 25739830 PMC4560667
  40. [44]Latourte A Soumare A Bardin T Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study Ann Rheum Dis 2018 77 3 328 335 28754803
  41. [46]Meier TB, Nitta ME, Teague TK, et al. Prospective study of the effects of sport-related concussion on serum kynurenine pathway metabolites. Brain Behav Immun. 2020. 10.1016/j.bbi.2020.03.002. PMC7316609 32147388 · DOI
  42. [47]Amaral M Levy C Heyes DJ Structural basis of kynurenine 3-monooxygenase inhibition Nature 2013 496 7445 382 385 23575632 PMC3736096
  43. [48]Zwilling D Huang SY Sathyasaikumar KV Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration Cell 2011 145 6 863 874 21640374 PMC3118409
  44. [49]Beconi MG Yates D Lyons K Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048 Drug Metab Dispos 2012 40 12 2297 2306 22942319
  45. [50]Sorgdrager FJH Vermeiren Y Van Faassen M Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease J Neurochem 2019 151 5 656 668 31376341 PMC6899862
  46. [51]Lin CH Lane HY The role of N-methyl-D-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia Front Pharmacol 2019 10 540 31191302 PMC6539199
  47. [52]Stone TW Stoy N Darlington LG An expanding range of targets for kynurenine metabolites of tryptophan Trends Pharmacol Sci 2013 34 2 136 143 23123095
  48. [53]Lin CH Chen PK Chang YC Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial Biol Psychiatry 2014 75 9 678 685 24074637
  49. [54]Modi KK Roy A Brahmachari S Cinnamon and its metabolite sodium benzoate attenuate the activation of p21rac and protect memory and learning in an animal model of Alzheimer's disease PLoS One 2015 10 6 e0130398 26102198 PMC4478015
  50. [55]Lin CH Lin CH Chang YC Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial Biol Psychiatry 2018 84 6 422 432 29397899
  51. [56]Lin CH Chiu CC Huang CH pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase Sci Rep 2019 9 1 13221 31520071 PMC6744481
  52. [57]Lin CH Yang HT Chiu CC Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging Sci Rep 2017 7 1 14849 29093468 PMC5665939
  53. [58]Xing Y Li X Guo X Simultaneous determination of 18 D-amino acids in rat plasma by an ultrahigh-performance liquid chromatography-tandem mass spectrometry method: application to explore the potential relationship between Alzheimer's disease and D-amino acid level alterations Anal Bioanal Chem 2016 408 1 141 150 26497841
  54. [59]Breda C Sathyasaikumar KV Sograte Idrissi S Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites Proc Natl Acad Sci U S A 2016 113 19 5435 5440 27114543 PMC4868470
  55. [60]van der Velpen V Teav T Gallart-Ayala H Systemic and central nervous system metabolic alterations in Alzheimer's disease Alzheimers Res Ther 2019 11 1 93 31779690 PMC6883620
  56. [61]Tanaka M, Bohar Z, Vecsei L. Are kynurenines accomplices or principal villains in dementia? Maintenance of kynurenine metabolism. Molecules. 2020;25(3):564. PMC7036975 32012948
  57. [63]Kubicova L, Hadacek F, Bachmann G, et al. Coordination complex formation and redox properties of kynurenic and xanthurenic acid can affect brain tissue homeodynamics. Antioxidants (Basel). 2019;8(10):476. PMC6826357 31614581
  58. [64]Jahan H Choudhary MI Atta A Anthranilic acid derivatives: novel inhibitors of protein glycation and the associated oxidative stress in the hepatocytes Med Chem 2018 14 5 516 523 29065839
  59. [65]Kwon IS Kwak JH Pyo S Oscarellin, an anthranilic acid derivative from a Philippine sponge, oscarella stillans, as an inhibitor of inflammatory cytokines in macrophages J Nat Prod 2017 80 1 149 155 28093915
  60. [66]Annweiler C Llewellyn DJ Beauchet O Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis J Alzheimers Dis 2013 33 3 659 674 23042216
  61. [67]Jia J Hu J Huo X Effects of vitamin D supplementation on cognitive function and blood Aβ-related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial J Neurol Neurosurg Psychiatry 2019 90 12 1347 1352 31296588
  62. [68]Littlejohns TJ Henley WE Lang IA Vitamin D and the risk of dementia and Alzheimer disease Neurology 2014 83 10 920 928 25098535 PMC4153851
  63. [69]Mehri N Haddadi R Ganji M Effects of vitamin D in an animal model of Alzheimer's disease: behavioral assessment with biochemical investigation of Hippocampus and serum Metab Brain Dis 2020 35 2 263 274 31853828
  64. [70]Medhat E Rashed L Abdelgwad M Exercise enhances the effectiveness of vitamin D therapy in rats with Alzheimer's disease: emphasis on oxidative stress and inflammation Metab Brain Dis 2020 35 1 111 120 31691146
  65. [71]Saad El-Din S Rashed L Medhat E Active form of vitamin D analogue mitigates neurodegenerative changes in Alzheimer's disease in rats by targeting Keap1/Nrf2 and MAPK-38p/ERK signaling pathways Steroids 2020 156 108586 31982424
  66. [72]Seshadri S Beiser A Selhub J Plasma homocysteine as a risk factor for dementia and Alzheimer's disease N Engl J Med 2002 346 7 476 483 11844848
  67. [73]Smith AD Refsum H Homocysteine, B vitamins, and cognitive impairment Annu Rev Nutr 2016 36 211 239 27431367
  68. [74]An Y Feng L Zhang X Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1 Clin Epigenetics 2019 11 1 139 31601260 PMC6787977
  69. [75]Zhang CE Wei W Liu YH Hyperhomocysteinemia increases β-amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain Am J Pathol 2009 174 4 1481 1491 19264913 PMC2671378
  70. [76]Guo J Ni S Li Q Folate/vitamin B alleviates hyperhomocysteinemia-induced Alzheimer-like pathologies in rat retina Neurosci Bull 2019 35 2 325 335 30264378 PMC6426902
  71. [77]Aisen PS Schneider LS Sano M High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 2008 300 15 1774 1783 18854539 PMC2684821
  72. [78]Sang S Pan X Chen Z Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not Alzheimers Res Ther 2018 10 1 26 29490669 PMC5831864
  73. [79]Gibson GE Blass JP Thiamine-dependent processes and treatment strategies in neurodegeneration Antioxid Redox Signal 2007 9 10 1605 1619 17685850
  74. [80]Heroux M Raghavendra Rao VL Lavoie J Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease Metab Brain Dis 1996 11 1 81 88 8815392
  75. [81]Mastrogiacoma F Bettendorff L Grisar T Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease Ann Neurol 1996 39 5 585 591 8619543
  76. [82]Bettendorff L Mastrogiacomo F Kish SJ Thiamine, thiamine phosphates, and their metabolizing enzymes in human brain J Neurochem 1996 66 1 250 258 8522961
  77. [83]Pan X Fei G Lu J Measurement of blood thiamine metabolites for Alzheimer's disease diagnosis EBioMedicine 2016 3 155 162 26870826 PMC4739421
  78. [84]Iuliano L Monticolo R Straface G Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease J Alzheimers Dis 2010 21 4 1383 1392 21504117
  79. [85]Sano M Ernesto C Thomas RG A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study N Engl J Med 1997 336 17 1216 1222 9110909
  80. [86]Petersen RC Thomas RG Grundman M Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 2005 352 23 2379 2388 15829527
  81. [88]Wang SW Yang SG Liu W α-Tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease Behav Brain Res 2016 296 109 117 26358659
  82. [89]Grimm MO, Regner L, Mett J, et al. Tocotrienol affects oxidative stress, cholesterol homeostasis and the amyloidogenic pathway in neuroblastoma cells: Consequences for Alzheimer's disease. Int J Mol Sci. 2016;17(11):1809. PMC5133810 27801864
  83. [91]Savelieff MG Lee S Liu Y Untangling amyloid-β, tau, and metals in Alzheimer's disease ACS Chem Biol 2013 8 5 856 865 23506614
  84. [93]Han J Lee HJ Kim KY Mechanistic approaches for chemically modifying the coordination sphere of copper-amyloid-β complexes Proc Natl Acad Sci U S A 2020 117 10 5160 5167 32102914 PMC7071886
  85. [94]Ward RJ Zucca FA Duyn JH The role of iron in brain ageing and neurodegenerative disorders Lancet Neurol 2014 13 10 1045 1060 25231526 PMC5672917
  86. [97]Chen YY Yu XY Chen L Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products Free Radic Biol Med 2019 141 141 149 31199964
  87. [98]Wilkinson BL Landreth GE The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease J Neuroinflammation 2006 3 30 17094809 PMC1637099
  88. [100]Zhou B Mu J Gong Y Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression Redox Biol 2017 11 390 402 28063381 PMC5219604
  89. [101]Wyss-Coray T Masliah E Mallory M Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease Nature 1997 389 6651 603 606 9335500
  90. [102]Perkins ND Integrating cell-signalling pathways with NF-κB and IKK function Nat Rev Mol Cell Biol 2007 8 1 49 62 17183360
  91. [103]Li LH Peng WN Deng Y Action of trichostatin a on Alzheimer's disease-like pathological changes in SH-SY5Y neuroblastoma cells Neural Regen Res 2020 15 2 293 301 31552902 PMC6905323
  92. [104]Ramalho MJ Andrade S Loureiro JA Nanotechnology to improve the Alzheimer's disease therapy with natural compounds Drug Deliv Transl Res 2020 10 2 380 402 31773421
  93. [105]Andrade S, Ramalho MJ, Loureiro JA, et al. Natural compounds for Alzheimer's disease therapy: A systematic review of preclinical and clinical studies. Int J Mol Sci. 2019;20(9):2313. PMC6539304 31083327
  94. [106]Newman DJ Cragg GM Natural products as sources of new drugs from 1981 to 2014 J Nat Prod 2016 79 3 629 661 26852623
  95. [107]Kunnumakkara AB Bordoloi D Padmavathi G Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases Br J Pharmacol 2017 174 11 1325 1348 27638428 PMC5429333
  96. [108]Lin L Li C Zhang D Synergic effects of berberine and curcumin on improving cognitive function in an Alzheimer's disease mouse model Neurochem Res 2020 45 5 1130 1141 32080784
  97. [109]Huo X Zhang Y Jin X A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease J Photochem Photobiol B 2019 190 98 102 30504054
  98. [110]Palmal S Maity AR Singh BK Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles Chemistry 2014 20 20 6184 6191 24691975
  99. [111]Teter B Morihara T Lim GP Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis Neurobiol Dis 2019 127 432 448 30951849 PMC8092921
  100. [113]Khan MS Muhammad T Ikram M Dietary supplementation of the antioxidant curcumin halts systemic LPS-induced neuroinflammation-associated neurodegeneration and memory/synaptic impairment via the JNK/NF-κB/Akt signaling pathway in adult rats Oxidative Med Cell Longev 2019 2019 7860650 PMC6885271 31827700
  101. [114]Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4(5):43. PMC3580400 23107780
  102. [115]Salehi B, Calina D, Docea AO, et al. Curcumin's nanomedicine formulations for therapeutic application in neurological diseases. J Clin Med. 2020;9(2):430. PMC7074182 32033365
  103. [116]Han Q Wang X Cai S Quercetin nanoparticles with enhanced bioavailability as multifunctional agents toward amyloid induced neurotoxicity J Mater Chem B 2018 6 9 1387 1393 32254423
  104. [117]Chen JY Zhu Q Zhang S Resveratrol in experimental Alzheimer's disease models: a systematic review of preclinical studies Pharmacol Res 2019 150 104476 31605783
  105. [118]Sgarbossa A Giacomazza D di Carlo M Ferulic acid: a hope for Alzheimer's disease therapy from plants Nutrients 2015 7 7 5764 5782 26184304 PMC4517023
  106. [119]Yang S Wang G Ma ZF Dietary advanced glycation end products-induced cognitive impairment in aged ICR mice: protective role of quercetin Mol Nutr Food Res 2020 64 3 e1901019 31860939
  107. [120]Sun XY Dong QX Zhu J Resveratrol rescues tau-induced cognitive deficits and neuropathology in a mouse model of tauopathy Curr Alzheimer Res 2019 16 8 710 722 31368873
  108. [121]Zhu CW Grossman H Neugroschl J A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study Alzheimers Dement (N Y) 2018 4 609 616 30480082 PMC6240843
  109. [122]Turner RS Thomas RG Craft S A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology 2015 85 16 1383 1391 26362286 PMC4626244
  110. [123]Wang R Yan H Tang XC Progress in studies of huperzine a, a natural cholinesterase inhibitor from Chinese herbal medicine Acta Pharmacol Sin 2006 27 1 1 26 16364207
  111. [124]Huang XT Qian ZM He X Reducing iron in the brain: a novel pharmacologic mechanism of huperzine a in the treatment of Alzheimer's disease Neurobiol Aging 2014 35 5 1045 1054 24332448
  112. [125]Qian ZM Ke Y Huperzine A Is it an effective disease-modifying drug for Alzheimer's disease? Front Aging Neurosci 2014 6 216 25191267 PMC4137276
  113. [126]Xu SS Gao ZX Weng Z Efficacy of tablet huperzine-a on memory, cognition, and behavior in Alzheimer's disease Zhongguo Yao Li Xue Bao 1995 16 5 391 395 8701750
  114. [127]Xu SS Cai ZY Qu ZW Huperzine-a in capsules and tablets for treating patients with Alzheimer disease Zhongguo Yao Li Xue Bao 1999 20 6 486 490 10678137
  115. [128]Rafii MS Walsh S Little JT A phase II trial of huperzine a in mild to moderate Alzheimer disease Neurology 2011 76 16 1389 1394 21502597 PMC3269774
  116. [129]Pei H, Ma L, Cao Y, et al. Traditional chinese medicine for Alzheimer's disease and other cognitive impairment: A review. Am J Chin Med. 2020. 10.1142/S0192415X20500251 1-25. 32329645 · DOI
  117. [130]Heidenreich PA Albert NM Allen LA Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association Circ Heart Fail 2013 6 3 606 619 23616602 PMC3908895
  118. [131]Huynh QL Negishi K De Pasquale CG Cognitive domains and postdischarge outcomes in hospitalized patients with heart failure Circ Heart Fail 2019 12 6 e006086 31146542
  119. [132]Agarwal KS Kazim R Xu J Unrecognized cognitive impairment and its effect on heart failure readmissions of elderly adults J Am Geriatr Soc 2016 64 11 2296 2301 27676328
  120. [133]Etgen T Chonchol M Forstl H Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis Am J Nephrol 2012 35 5 474 482 22555151
  121. [134]Shi Y Liu Z Shen Y A novel perspective linkage between kidney function and Alzheimer's disease Front Cell Neurosci 2018 12 384 30429775 PMC6220726
  122. [136]Seliger SL Longstreth WT Jr Lessons about brain vascular disease from another pulsating organ, the kidney Stroke 2008 39 1 5 6 18048859
  123. [137]Chen H Yang T Wang MC Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation Phytomedicine 2018 42 207 218 29655688
  124. [138]Wang M Chen DQ Chen L Novel RAS inhibitors poricoic acid ZG and poricoic acid ZH attenuate renal fibrosis via a Wnt/β-catenin pathway and targeted phosphorylation of Smad3 signaling J Agric Food Chem 2018 66 8 1828 1842 29383936
  125. [139]Wang M Chen DQ Chen L Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis Br J Pharmacol 2018 175 13 2689 2708 29679507 PMC6003649
  126. [140]Chen DQ Feng YL Chen L Poricoic acid a enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNF-κB/Nrf2 axis Free Radic Biol Med 2019 134 484 497 30716432
  127. [141]Chen L Cao G Wang M The matrix metalloproteinase-13 inhibitor poricoic acid ZI ameliorates renal fibrosis by mitigating epithelial-mesenchymal transition Mol Nutr Food Res 2019 63 13 e1900132 30925007

Cited by

Sorted by citations

Authors
Chen, Y.-Y., Wang, M.-C., Wang, Y.-N., Hu, H.-H., Liu, Q.-Q., Liu, H.-J., & Zhao, Y.-Y.
Affiliations
Northwest University (CN)
Corresponding author
Zhao, Ying-Yong
ORCID
Zhao, Ying-Yong
Venue
Biomarker Research
Publisher
Springer Science and Business Media LLC
Published
2020-09-11
Volume
8
Issue
1
Pages
42-42
ISSN
2050-7771 (ISSN-L)
DOI
10.1186/s40364-020-00218-z
PMC
PMC7488504
OpenAlex
W3085682383
Cited by
33
References
12
Citations by year
2026: 3 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 3
FWCI
0.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomarker Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Project of China (2019YFC1709405)
  • National Natural Science Foundation of China (81603271, 81872985, 81673578)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
Alzheimer's disease, redox signaling, oxidative stress, metabolomics, biomarker discovery, metabolic pathways, neurodegeneration, natural products, treatment options, aging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review